WHO Unveils 2026–2030 Strategy to Reduce Childhood Cancer Medicine Shortages

The World Health Organization (WHO)has published a five year plan to fix one of the starkest gaps in global health: children in poorer countries dying of cancers that are curable, because the medicines to treat them are not reliably available, affordable, or safe.

The report, titled Closing the childhood cancer survival gap through sustainable access to medicines: market shaping strategy 2026–2030 published on September 15,2026, sets out ten specific interventions WHO wants governments, drug manufacturers, and health partners to carry out over the next five years.

The numbers behind the plan explain why WHO is treating this as urgent. An estimated 400,000 children and adolescents develop cancer every year worldwide, and about 90% of them live in low- and middle-income countries, the report says.

In wealthy nations, more than 80% of children with cancer survive at least five years after diagnosis, whereas in many low- and middle-income countries, fewer than 30% do.

Highlighting persistent regional inequities, a WHO study on lymphoid leukaemia across 194 Member States showed survival rates sitting closer to 40% in some regions while approaching or exceeding 80 to 90% in others.

What makes that gap especially hard to accept, according to WHO, is that it is not mainly a science problem.

Most childhood cancers respond well to chemotherapy drugs that have existed for decades and are largely off patent, meaning they should be cheap and simple to produce.

The report states that survival now depends less on new drug discoveries and more on whether a sick child is diagnosed early, referred to proper care, and able to get an uninterrupted course of treatment, something that keeps failing because the medicines themselves are not reaching hospitals.

A market that keeps failing children

The report lays out, in blunt figures, how deep that failure runs.

Close to 70% of children in low income countries and lower middle income countries live in places where essential childhood cancer medicines are in short supply.

Fewer than 60% of these essential medicines are reliably available at hospital level across low and middle income countries.

And a baseline assessment carried out across 12 countries before the strategy was developed found that only about 45% of essential cancer medicines were available in the 51 hospitals visited, with almost half of those drugs, even when officially on the hospital's procurement list, out of stock for at least a month at some point in the previous year.

Regional data cited in the report paints a similar picture.

Hospitals in East Africa reported stockouts affecting between 32% and 49% of critical chemotherapy drugs, including methotrexate and etoposide, both standard treatments for childhood leukaemias.

A 2025 survey covering 137 institutions in 19 Latin American countries found access to paediatric cancer medicines "remains uneven," reflecting how differently health systems are financed and organised from one country to the next.

Quality is a separate danger on top of supply.

The report cites a 2025 investigation finding that one in five oncology medicines tested across four countries in Sub-Saharan Africa was substandard or falsified, meaning a drug on the shelf may not actually contain what it claims to, or enough of it to work.

That investigation focused on seven cancer medicines, including cisplatin, methotrexate and doxorubicin.

Cost adds a third layer of harm.

Families of children with cancer in low- and middle-income countries frequently face what the report calls "catastrophic health expenditure," with cancer treatment costs exceeding 40% of a household's entire annual income.

WHO links this financial strain directly to worse long-term outcomes and quality of life for the children involved, since families who cannot sustain the cost of treatment are more likely to interrupt it.

The platform already moving medicine

The strategy builds on a programme WHO has been running since 2021 called the Global Platform for Access to Childhood Cancer Medicines.

It is a partnership between WHO and St. Jude Children's Research Hospital in the United States, working with UNICEF and the Pan American Health Organization's Strategic Fund, which pools orders from multiple countries and negotiates long term supply agreements with drug manufacturers, rather than leaving each country to negotiate, and often fail to secure supply, on its own.

According to the report, the first medicines under this platform reached health facilities starting in February 2025 for a first cohort of six pilot countries: Ecuador, Jordan, Mongolia, Nepal, Uzbekistan, and Zambia.

A second group of countries followed, starting with the Republic of Moldova in February 2026, with El Salvador, Ghana, Pakistan, Senegal, and Sri Lanka expected to receive their first shipments within the year.

By June 2026, the platform had delivered 1.7 million standard units of medicine to 31 health facilities, and more than 5,400 children had benefited.

As of August 2026, the platform's approved list covered 33 medicines available in 45 different product formulations.

In Ecuador, the report notes, the platform's impact has gone beyond simply supplying drugs.

The country used the partnership to help set up a National Commission for Childhood and Adolescent Cancer, pass a 2025 law on comprehensive cancer care, and lean on its existing vaccine cold chain and logistics systems to support the safe delivery of chemotherapy, evidence, WHO argues, that fixing medicine supply chains can strengthen a country's broader health system.

Why the market itself is broken

The new strategy does not treat these shortages as one off supply hiccups.

It frames them as the predictable result of a "broken market" for childhood cancer medicines, built on root causes that a single country, or a single donation, cannot fix.

The report identifies these root causes as: a very small patient population for any individual childhood cancer medicine, which gives manufacturers little commercial incentive to keep producing it; chronically limited financing for medicines in poorer countries; a lack of reliable market information for both suppliers and buyers; high costs of keeping a drug's manufacturing and regulatory approvals current over its lifecycle; and weak regulatory capacity in many of the countries that need the drugs most.

Those root causes then produce specific barriers, according to WHO: a fragile group of manufacturers making quality assured versions of these drugs, meaning supply can collapse if even one producer exits the market; demand from health systems that is fragmented, uncertain, and underfunded, making it hard for manufacturers to plan production; slow and duplicative product registration processes in many countries; and very limited investment in the child specific dosages and formulations, such as syrups or smaller tablet strengths, that paediatric patients actually need, since most cancer drug development is designed around adult patients.

Ten fixes, phased over five years

To address this, the strategy proposes ten "market shaping interventions," grouped into three phases running from now through 2030.

The near term priorities, targeted for 2026 to 2027, focus on stabilising supply and consolidating demand.

They include broadening engagement with pharmaceutical manufacturers, expanding the pool of quality assured suppliers, including through WHO's own prequalification programme, helping countries speed up drug registration through reliance on other regulators' approvals, expanding access to the platform's pooled procurement system, deploying volume guarantees and other tools to reduce manufacturers' financial risk, and publishing global demand forecasts so suppliers can plan production with more confidence.

Medium term priorities, beginning from 2027, shift toward building visibility and long term sustainability.

These include identifying gaps in research and development and defining "target product profiles," technical specifications for the medicines still missing from the market, publishing product roadmaps and price benchmarks, and supporting countries to fold childhood cancer medicines permanently into their national health benefit packages, so access does not depend indefinitely on external donors.

The long term priority, from 2029, is supporting innovation: using tools such as voluntary licensing and intellectual property pooling to help newer cancer therapies reach low and middle income countries once the market for older, essential medicines is stable enough to absorb them.

WHO says the sequencing is deliberate. Stabilising the supply of older, essential medicines first is meant to build the regulatory and procurement track record that makes it easier, later, for countries to integrate cancer drugs into national budgets and eventually gain access to newer treatments as they become available.

What officials are saying

Dr Jeremy Farrar, WHO's Assistant Director General for Health Promotion, Disease Prevention and Care, said in the report's foreword that the ten interventions were "evidence based, practical, and feasible," and argued lessons from the strategy could extend to other diseases facing similar access problems.

"No child should die of a curable cancer because of market failure," he wrote, adding that with the strategy and through partnership, "we can ensure that no child does."

Dr Carlos Rodriguez-Galindo, Executive Vice President of St. Jude Children's Research Hospital and Director of St. Jude Global, said the Global Platform and the new strategy were meant to tackle "the underlying market challenges that have limited access to childhood cancer medicines for far too long," working with governments, industry, civil society, and health professionals.

"By creating healthier and more sustainable markets, we can help ensure that every child, everywhere, has a fair opportunity to receive life saving treatment," he said.

What it means going forward

The strategy itself does not supply a single dose of medicine. It is a coordination plan, and its success depends on whether governments, manufacturers, and donors actually follow through on the ten interventions over the next five years.

WHO's own framing is cautious on this point: the report describes "important trade-offs" in how pricing and overall system costs are shaped by fragmented demand, limited incentive for manufacturers, and regulatory complexity, meaning no single intervention is likely to fix access on its own.

Still, the report treats the platform's early record of more than 5,400 children reached across seven countries since February 2025 as proof that pooling demand and coordinating supply across countries can move medicine faster than each country negotiating alone. Whether that model can be scaled to the tens of thousands of children still going without treatment each year, in the numbers the strategy itself lays out, is what the next five years will test.

Source: World Health Organization, Closing the childhood cancer survival gap through sustainable access to medicines: market shaping strategy 2026–2030, Geneva, published September 15, 2026.